IL-33 Polyclonal Antibody, PeproTech®, Invitrogen™

Rabbit Polyclonal Antibody

Catalog Number	Mfr. No.	Quantity
500P261100	Invitrogen™ 500P261100UG	100 μg
500P2611MG	Invitrogen™ 500P2611MG	1 mg

Description

AA Sequence of recombinant protein: SITGISPITE YLASLSTYND QSITFALEDE SYEIYVEDLK KDEKKDKVLL SYYESQHPSN ESGDGVDGKM LMVTLSPTKD FWLHANNKEH SVELHKCEKP LPDQAFFVLH NMHSNCVSFE CKTDPGVFIG VKDNHLALIK VDSSENLCTE NILFKLSET. Preparation: Produced from sera of rabbits immunized with highly pure Recombinant Human IL-33. Anti-Human IL-33-specific antibody was purified by affinity chromatography employing an immobilized Human IL-33 matrix. Sandwich ELISA: To detect Human IL-33 by sandwich ELISA (using 100 μL/well antibody solution) a concentration of 0.5-2.0 μg/mL of this antibody is required. This antigen affinity purified antibody, in conjunction with PeproTech Biotinylated Anti-Human IL-33 (500-P261Bt) as a detection antibody, allows the detection of at least 0.2-0.4 ng/well of Recombinant Human IL-33. Western Blot: To detect Human IL-33 by Western Blot analysis this antibody can be used at a concentration of 0.1-0.2 μg/mL. Used in conjunction with compatible secondary reagents the detection limit for Recombinant Human IL-33 is 1.5-3.0 ng/lane, under either reducing or non-reducing conditions.

IL-33 (Interleukin-33) is a 270 amino acid, highly divergent protein belonging to the IL-1 family with an IL-1-like C-terminal domain. IL-33 is a dual function protein that may function both as a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties. IL-33 binds to and signals through IL1RL1/ST2 and its stimulation recruits MYD88, IRAK1, IRAK4, and TRAF6. IL-33 activates NF-kappaB and MAP kinases, and drives production of TH2-associated cytokines from in vitro polarized TH2 cells. In vivo, IL-33 induces the expression of IL-4, IL-5, and IL-13 and leads to severe pathological changes in mucosal organs. IL-33 is proteolytically converted to a mature form by CASP1 and is highly expressed in high endothelial venules found in tonsils, Peyer's patches and mesenteric lymph nodes and is almost undetectable in placenta. Prolonged IL-33 treatment of mice led to the development of eosinophilia, splenomegaly, and severe pathological changes in mucosal organs such as lungs, esophagus and small intestine. Recent experiments have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine and an intracellular nuclear factor with transcriptional regulatory properties. Despite its predicted molecular weight, IL-33 will often run at higher molecular weight in SDS-PAGE. Studies have shown that IL-33 can also co-localize with heterochromatin and possesses transcriptional repressor activities, indicating that IL-33 may function as both a proinflammatory cytokine, and an intracellular nuclear factor with transcriptional regulatory properties.

Specifications

• Antigen: IL-33
• Applications: ELISA, Western Blot
• Conjugate: Unconjugated
• Host Species: Rabbit
• Target Species: Human
• Gene Accession No.: O95760, Q01638
• Gene ID (Entrez): 90865, 9173
• Immunogen: E.coli-derived Recombinant Human IL-33.
• Purification Method: Antigen Affinity Chromatography
• Gene: IL33

• Concentration: 0.1-1.0 mg/mL
• Classification: Polyclonal
• Form: Lyophilized
• Regulatory Status: RUO
• Formulation: PBS with no preservative
• Gene Alias: 9230117N10Rik; C9orf26; DVS27; DVS27-related protein; H-IL-33; IL1F11; IL-1F11; Il33; IL-33; ILN; Interleukin; interleukin 33; interleukin-1 family member 11; Interleukin33; Interleukin-33; Interleukin-33 (109-270); Interleukin-33 (95-270); Interleukin-33 (99-270); Interleukin-33(102-266); Interleukin-33(109-266); NFEHEV; NFHEV; NF-HEV; nuclear factor for high endothelial venules; nuclear factor from high endothelial venules; RGD1311155; RP11-575C20.2
• Gene Symbols: IL1rl1, IL33
• Primary or Secondary: Primary
• Content And Storage: -20°C